This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter: revenue up 7.9%, profit after tax up 21.9%, margin expands
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Midcap 150 and 1.9 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unaudited consolidated quarter ended September 30, 2026: revenue Rs594.03 crore, up 7.9% from Rs550.50 crore a year earlier; profit after tax Rs211.46 crore, up 21.9% from Rs173.43 crore. Operating earnings before interest, tax and depreciation were 45.7% of revenue, up from 39.7%. Consolidated half year ended September 30, 2026: cash from operations Rs31.82 crore; interest income from deposits, bonds and related-party loans was Rs70.64 crore.
Revenue and profit grew while the operating earnings margin expanded 6.0 points, supporting sentiment; related-party loans warrant monitoring.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹594.0 Cr | ₹550.0 Cr | +8.0% |
| Operating profit | ₹237.5 Cr | ₹181.4 Cr | +30.9% |
| Profit after tax | ₹211.5 Cr | ₹173.4 Cr | +21.9% |
| EBITDA margin | 45.7% | 39.6% | +6.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.